Weekly tirzepatide led to significant, sustained weight loss in adults with obesity in the 72-week phase 3 SURMOUNT-1 trial. Supported by AMR Clinical sites, the study found that over 85% of participants on tirzepatide achieved at least 5% weight loss and up to 57% lost 20% or more. The treatment also improved key cardiometabolic measures and was generally well tolerated.
Read this publication to explore:
- Percentage of participants reaching 5%, 10%, and 20%+ weight loss
- Outcomes by tirzepatide dose (5 mg, 10 mg, 15 mg) vs placebo
- Safety and tolerability